# US 2019/0314499 A1 · Etanercept Formulations Stabilized with Sodium Chloride

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314499 A1
- Document ID: US20190314499A1
- Status: Published application
- Kind: A1
- Application number: 16/453,154
- Filed: 2019-06-26
- Published: 2019-10-17
- Earliest claimed: 2011-10-18
- Assignees: Coherus Biosciences, Inc.
- Applicants: Coherus Biosciences, Inc.
- Inventors: Mark MANNING; Brian Murphy
- Web page: https://patentgrep.com/patent/US20190314499A1

## CPC

- A61K 38/191: {Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 38/1793: {for cytokines; for lymphokines; for interferons}
- A61K 39/39591: {Stabilisation, fragmentation}
- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K 47/68: the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 17/00: Drugs for dermatological disorders
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 14/7151: {for tumor necrosis factor [TNF], for lymphotoxin [LT]}
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 9/16: Agglomerates; Granulates; Microbeadlets {; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction (A61K9/20 takes precedence if the final form is a tablet; microspheres with drug-free outer coating, microcapsules A61K9/50; mixture of different granules, microcapsules, (coated) microparticles A61K9/5084; nanoparticles A61K9/51)}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.

## Claims

### Claim 1

A method of reducing formation of etanercept aggregates or fragments in a composition containing 25 to 75 mg/ml etanercept, the method comprising combining 25 to 75 mg/ml etanercept with up to 150 mM sodium chloride, 1 to 30 mM sodium phosphate, and 3 to 5 wt. % sucrose in an aqueous pharmaceutical composition, wherein the aqueous pharmaceutical composition is free or essentially free of arginine, thereby preparing a stable aqueous etanercept composition.

### Claim 2 (depends on 1)

The method of claim 1, further comprising adding one or more additional components selected from: a buffer; a tonicity modifier, and an excipient to the aqueous pharmaceutical composition.

### Claim 3 (depends on 2)

The method of claim 2, wherein the aqueous pharmaceutical composition has a pH of about 6.0 to about 6.6.

### Claim 4 (depends on 1)

The method of claim 1, wherein the stable aqueous etanercept composition elicits long term storage stability as characterized by: an HIC analysis at M3 or T2 or T4 wherein the amount of the stable aqueous etanercept composition represented by peak 2 of the HIC chromatogram is greater than or equal to 95 wt. %; and wherein, if peak 3 is present on the HIC chromatogram, the amount of the composition represented by peak 3 is less than or equal to about 3 wt. %.

### Claim 5 (depends on 1)

The method of claim 1, wherein the stable aqueous etanercept composition has no more than, on average, about 10,000 subvisible particles per mL having a size greater than 5 μm.

### Claim 6 (depends on 1)

The method of claim 1, wherein the stable aqueous etanercept composition elicits long term storage stability as characterized by at least one of:
SEC analysis at M3 or T2 or T4 of: monomer content greater than about 90%;
aggregates content of less than about 3 wt. %; and
fragment 3 content less than about 5 wt. %.

### Claim 7 (depends on 1)

The method of claim 1, wherein etanercept is at a concentration of 50 mg/ml and wherein sodium chloride is at a concentration of 75 mM.

### Claim 8 (depends on 1)

The method of claim 1, wherein the stable aqueous etanercept composition comprises 10 mM or 25 mM sodium phosphate.

### Claim 9 (depends on 1)

The method of claim 1, wherein the stable aqueous etanercept composition comprises 25 to 75 mg/ml of etanercept, up to 150 mM sodium chloride, 10 to 25 mM sodium phosphate, and 3 to 5 wt. % trehalose, and is free of arginine.

### Claim 10 (depends on 1)

The method of claim 1, wherein the stable aqueous etanercept composition comprises 50 mg/ml etanercept, 75 mM sodium chloride, and 25 mM sodium phosphate.

### Claim 11 (depends on 1)

The method of claim 1, wherein the stable aqueous etanercept composition elicits long term storage stability as characterized by at least one of: HIC analysis at M3 or T2 or T4 wherein the amount of the composition represented by peak 1 of the HIC chromatogram is less than about 3 wt. %; the amount of the composition represented by peak 2 of the HIC chromatogram is greater than 80 wt. %; and the amount of the composition represented by peak 3 of the HIC chromatogram is less than about 20 wt. %.

### Claim 12 (depends on 1)

The method of claim 1, wherein the stable aqueous etanercept composition, at M3 or T2 or T4, elicits long term storage stability that meets the following criteria:
(A) an SEC analysis of: monomer content greater than about 90%; aggregates content of less than about 3 wt. %; and fragment 3 content less than about 5 wt. %; and
(B) an HIC analysis wherein the amount of the composition represented by peak 1 of the HIC chromatogram is less than about 3 wt. %; the amount of the composition represented by peak 2 of the HIC chromatogram is greater than 80 wt. %; and the amount of the composition represented by peak 3 of the HIC chromatogram is less than about 20 wt. %.

### Claim 13

A method of treating a subject in need of treatment by injection of etanercept comprising administering to the subject a stable aqueous etanercept composition comprising 25 to 75 mg/ml etanercept, the method comprising combining 25 to 75 mg/ml etanercept with up to 150 mM sodium chloride, 1 to 30 mM sodium phosphate, and 3 to 5 wt. % sucrose in an aqueous pharmaceutical composition, wherein the aqueous pharmaceutical composition is free or essentially free of arginine.

### Claim 14 (depends on 13)

The method of claim 13, comprising administering 25-100 mg etanercept per dose to the subject.

### Claim 15 (depends on 13)

The method of claim 13, comprising injecting the stable aqueous etanercept composition subcutaneously or intramuscularly.

### Claim 16

A method of treating a subject in need of treatment for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Wegener's disease (granulomatosis), Crohn's disease (or inflammatory bowel disease), chronic obstructive pulmonary disease (COPD), Hepatitis C, endometriosis, asthma, cachexia, psoriasis, or atopic dermatitis comprising administering to the subject a stable aqueous etanercept composition comprising 25 to 75 mg/ml etanercept, the method comprising combining 25 to 75 mg/ml etanercept with up to 150 mM sodium chloride, 1 to 30 mM sodium phosphate, and 3 to 5 wt. % sucrose in an aqueous pharmaceutical composition, wherein the aqueous pharmaceutical composition is free or essentially free of arginine.

### Claim 17 (depends on 16)

The method of claim 16, comprising administering 25-100 mg etanercept per dose to the subject.

### Claim 18 (depends on 16)

The method of claim 16, wherein the administering comprises injecting the stable aqueous etanercept composition subcutaneously or intramuscularly.

### Claim 19

A vial, syringe, or injector pen containing a stable aqueous etanercept composition comprising 25 to 75 mg/ml etanercept, the method comprising combining 25 to 75 mg/ml etanercept with up to 150 mM sodium chloride, 1 to 30 mM sodium phosphate, and 3 to 5 wt. % sucrose in an aqueous pharmaceutical composition, wherein the aqueous pharmaceutical composition is free or essentially free of arginine.

### Claim 20 (depends on 19)

The vial, syringe, or injector pen of claim 19, wherein the stable aqueous pharmaceutical composition has a pH of about 6.0 to about 6.6.
